Compare Riot Platforms Inc (RIOT) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance

RIOT trades at $16.67, up 1.21% today, while showing bearish technical signals with 13 of 13 moving averages indicating sell signals. The company reported significant losses with a net income margin of -196.28% in 2026 and has missed earnings expectations for three consecutive quarters. However, analyst sentiment remains overwhelmingly positive with 94.74% buy ratings and a $31.64 consensus price target, reflecting optimism about the company's strategic shift toward data center operations and AI power capacity.

RIOT faces substantial fundamental challenges with persistent losses and negative cash flow, but the company's pivot to data center landlord strategy with $9.8 billion in contracted lease revenue through 2048 provides long-term revenue visibility. The stock offers significant upside potential if management can execute the business transition successfully, though investors must weigh the high valuation multiples against ongoing profitability concerns and execution risks in the competitive AI infrastructure market.

Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.

The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.